Viridian Therapeutics Inc
$ 31.54
-1.07%
29 Dec - close price
- Market Cap 3,042,691,000 USD
- Current Price $ 31.54
- High / Low $ 31.89 / 31.25
- Stock P/E N/A
- Book Value 3.82
- EPS -3.03
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -0.50 %
- 52 Week High 34.04
- 52 Week Low 9.90
About
Viridian Therapeutics, Inc. is an innovative biopharmaceutical company headquartered in Boulder, Colorado, dedicated to advancing therapies for rare and autoimmune disorders. Leveraging cutting-edge research and development, the company is committed to addressing significant unmet medical needs through its promising pipeline of drug candidates. With a strong focus on improving patient outcomes, Viridian Therapeutics is well-positioned to lead transformative changes in the treatment of severe diseases, establishing itself as a pivotal player within the biopharmaceutical landscape.
Analyst Target Price
$41.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-25 | 2024-11-11 | 2024-08-08 | 2024-05-08 | 2024-02-27 | 2023-11-13 | 2023-08-08 | 2023-05-09 | 2023-03-08 |
| Reported EPS | -0.34 | -1 | -0.869 | -0.81 | -1.1546 | -1.02 | -0.79 | -1.35 | -1.09 | -1.27 | -1.61 | -1.13 |
| Estimated EPS | -0.9532 | -1 | -1.1 | -1.0442 | -1.06 | -0.89 | -1.1 | -1 | -1.27 | -1.29 | -1.02 | -0.73 |
| Surprise | 0.6132 | 0 | 0.231 | 0.2342 | -0.0946 | -0.13 | 0.31 | -0.35 | 0.18 | 0.02 | -0.59 | -0.4 |
| Surprise Percentage | 64.3307% | 0% | 21% | 22.4287% | -8.9245% | -14.6067% | 28.1818% | -35% | 14.1732% | 1.5504% | -57.8431% | -54.7945% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.9558 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VRDN
2025-12-29 11:09:18
Viridian Therapeutics, Inc. (NASDAQ:VRDN) has received a "Moderate Buy" consensus rating from thirteen brokerages, with an average 12-month price target of $41.75. The company recently reported better-than-expected quarterly earnings, though it remains unprofitable. Insider and institutional buying activity has increased, with major funds like Fairmount Funds and Wellington Management Group significantly raising their stakes.
2025-12-27 12:09:34
Rice Hall James & Associates LLC significantly increased its stake in Viridian Therapeutics (NASDAQ:VRDN) by 65.2% in the third quarter, acquiring 336,040 additional shares. This institutional investor now holds 851,663 shares valued at approximately $18.38 million. The increase follows Viridian Therapeutics' strong quarterly results, which surpassed analyst expectations for both EPS and revenue, and a "Moderate Buy" consensus rating from analysts with an average target price of $41.75.
2025-12-24 14:09:18
This article details recent analyst ratings for several healthcare companies. Viridian Therapeutics (VRDN) received a "Strong Buy" consensus with a significant upside, while Fortrea Holdings Inc. (FTRE) garnered a "Hold" consensus with a projected downside. Cytokinetics (CYTK) also received a "Strong Buy" consensus from analysts, indicating a substantial potential upside.
2025-12-23 13:08:27
Needham & Company LLC has raised its price target for Viridian Therapeutics (NASDAQ:VRDN) to $42.00 from $34.00, maintaining a "buy" rating, indicating a potential upside of 29.35%. This update follows an earnings beat by Viridian, with EPS of ($0.34) versus an estimated ($0.82) and revenue of $70.57 million against an estimated $16.21 million. The company has a "Moderate Buy" consensus rating from analysts, with an average price target of $41.75, and recently saw significant insider buying.
2025-12-23 12:08:27
William Blair analyst Lachlan Hanbury Brown has reiterated a "Buy" rating for Viridian Therapeutics (VRDN) due to its lead program, veligrotug, becoming de-risked. The FDA's acceptance of the biologics license application, along with priority review and a PDUFA date of June 30, 2026, signals strong regulatory confidence. Robust Phase III data showing significant efficacy in thyroid eye disease and convenience advantages over existing treatments further support the positive outlook, suggesting Viridian's shares are currently undervalued.
2025-12-22 16:08:27
Viridian Therapeutics announced that the FDA has accepted its Biologics License Application (BLA) for veligrotug, a treatment for thyroid eye disease (TED), granting it Priority Review. This designation shortens the review timeline to six months, with a PDUFA target action date of June 30, 2026. The Priority Review, along with a prior Breakthrough Therapy Designation, was supported by Phase 3 clinical trial data showing veligrotug's effectiveness in improving and resolving diplopia and rapidly reducing proptosis in TED patients.
